{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:29:27Z","timestamp":1794580167464,"version":"4.9.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Letermovir is used for cytomegalovirus prophylaxis after allogeneic hematopoietic cell transplantation (HCT) and reportedly increases tacrolimus exposure. Isavuconazole, a mold-active triazole antifungal, also inhibits cytochrome P450 3A and may affect tacrolimus pharmacokinetics. This retrospective study evaluated tacrolimus concentration-to-dose (C\/D) ratios pre- and post-conversion from continuous intravenous infusion to oral administration in allogeneic HCT recipients receiving isavuconazole. Forty-five patients were stratified according to letermovir coadministration into the isavuconazole-alone group (ISCZ-alone; n\u00a0=\u00a09) and the isavuconazole with letermovir group (ISCZ + LMV; n\u00a0=\u00a036). The median C\/Dciv ratios were 17.00 and 16.40 (ng\/ml)\/(mg\/day), respectively (P\u00a0=\u00a00.81); the median C\/Dpo ratios were 3.25 and 2.60 (ng\/ml)\/(mg\/day), respectively (P\u00a0=\u00a00.77); and the median (C\/Dpo)\/(C\/Dciv) ratios were 0.154 and 0.173, respectively (P\u00a0=\u00a00.72). Sensitivity analyses yielded consistent findings. Letermovir coadministration was not associated with significant differences in tacrolimus C\/D ratios pre- or post-conversion to oral administration in allogeneic HCT recipients receiving isavuconazole.<\/jats:p>","DOI":"10.1093\/jjco\/hyag135","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:45:12Z","timestamp":1785843912000},"page":"1455-1460","source":"Crossref","is-referenced-by-count":0,"title":["Letermovir coadministration and tacrolimus concentration-to-dose ratios before and after intravenous-to-oral conversion in allogeneic hematopoietic stem cell transplant recipients receiving isavuconazole"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-2502","authenticated-orcid":false,"given":"Toshihisa","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Japan Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Japan Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Japan Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Japan Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cancer Center Japan Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026111309180547800_ref1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/eri.11.13","article-title":"Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation","volume":"9","author":"Salman","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026111309180547800_ref2","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1086\/652768","article-title":"Factors associated with mortality in transplant patients with invasive aspergillosis","volume":"50","author":"Baddley","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026111309180547800_ref3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026111309180547800_ref4","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2026111309180547800_ref5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Bogler","year":"2021","journal-title":"Med Mycol"},{"key":"2026111309180547800_ref6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A single-center, open-label trial of Isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation","volume":"26","author":"Stern","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026111309180547800_ref7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"2026111309180547800_ref8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of Isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026111309180547800_ref9","doi-asserted-by":"publisher","first-page":"e13007","DOI":"10.1111\/tid.13007","article-title":"Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: a drug-drug interaction study","volume":"21","author":"Kieu","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2026111309180547800_ref10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of Letermovir Coadministered with cyclosporine a or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026111309180547800_ref11","doi-asserted-by":"publisher","first-page":"371.e1","DOI":"10.1016\/j.jtct.2022.03.028","article-title":"Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplantation recipients","volume":"28","author":"Marciano","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026111309180547800_ref12","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/10781552221139772","article-title":"Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis","volume":"29","author":"Malespini","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"2026111309180547800_ref13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12185-021-03277-6","article-title":"Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal","volume":"115","author":"Nakashima","year":"2022","journal-title":"Int J Hematol"},{"key":"2026111309180547800_ref14","doi-asserted-by":"publisher","first-page":"e01120","DOI":"10.1002\/prp2.1120","article-title":"Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: a retrospective observational analysis","volume":"11","author":"Shinogi","year":"2023","journal-title":"Pharmacol Res Perspect"},{"key":"2026111309180547800_ref15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s12185-025-03942-0","article-title":"Concomitant letermovir affects the optimal concentration-to-dose ratio of tacrolimus after switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving fluconazole prophylaxis","volume":"121","author":"Nakashima","year":"2025","journal-title":"Int J Hematol"},{"key":"2026111309180547800_ref16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/jjco\/hyaf101","article-title":"The optimal conversion ratio of tacrolimus switching from intravenous to oral tacrolimus administration in hematopoietic cell transplantation patients receiving posaconazole prophylaxis with and without letermovir","volume":"55","author":"Nakashima","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026111309180547800_ref17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12185-016-2135-7","article-title":"Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation","volume":"105","author":"Suetsugu","year":"2017","journal-title":"Int J Hematol"},{"key":"2026111309180547800_ref18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/FTD.0000000000000793","article-title":"Clinical factors affecting the dose conversion ratio from intravenous to oral tacrolimus formulation among pediatric hematopoietic stem cell transplantation recipients","volume":"42","author":"Kanamitsu","year":"2020","journal-title":"Ther Drug Monit"},{"key":"2026111309180547800_ref19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.transproceed.2005.02.076","article-title":"Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy","volume":"37","author":"Nakamura","year":"2005","journal-title":"Transplant Proc"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/11\/1455\/70685432\/hyag135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/11\/1455\/70685432\/hyag135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:18:12Z","timestamp":1794579492000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/11\/1455\/8763874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,11,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag135","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,18]]}}}